{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:00:19Z","timestamp":1791262819650,"version":"4.1.0"},"reference-count":45,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,5,12]],"date-time":"2011-05-12T00:00:00Z","timestamp":1305158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2011,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The incorporation of rituximab into various regimens has improved depth of response in Waldenstrom macroglobulinaemia (WM), though the impact of achieving better responses remains to be determined. We examined response depth on progression\u2010free survival (PFS) in 159 rituximab\u2010na\u00efve WM patients who received rituximab\u2010based therapy. The median follow\u2010up was 33\u00b75\u2003months, and categorical responses were as follows: complete response (CR, 8\u00b78%); very good partial response (VGPR, 13\u00b72%); partial response (50%); minor response (18\u00b79%); Non\u2010Responders (8\u00b78%). Sequencing for polymorphic variants of <jats:italic>FCGR2A<\/jats:italic>, <jats:italic>FCGR2B<\/jats:italic>, and <jats:italic>FCGR3A<\/jats:italic> was performed, and impact on response depth determined. Achievement of better categorical responses was incrementally associated with improved PFS (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b70001). No separation was observed between CR and VGPR, and attainment of at least a VGPR was associated with improved time\u2010to\u2010progression. Neither age, serum IgM, haematocrit, platelet count, serum \u03b2<jats:sub>2<\/jats:sub>microglobulin, WM International Prognostic Scoring System score, and treatment group predicted for CR\/VGPR. Polymorphisms at <jats:italic>FCGR3A<\/jats:italic>\u201048 and \u2010158 were associated with improved categorical responses, particularly attainment of CR\/VGPR (<jats:italic>P<\/jats:italic>\u2003\u2264\u20030\u00b703). The attainment of CR\/VGPR was associated with significantly longer PFS in rituximab\u2010na\u00efve WM patients undergoing rituximab\u2010based therapy, and was predicted by polymorphisms in <jats:italic>FCGR3A<\/jats:italic>.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2011.08726.x","type":"journal-article","created":{"date-parts":[[2011,5,12]],"date-time":"2011-05-12T12:16:22Z","timestamp":1305202582000},"page":"223-228","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Attainment of complete\/very good partial response following rituximab\u2010based therapy is an important determinant to progression\u2010free survival, and is impacted by polymorphisms in <i>FCGR3A<\/i> in Waldenstrom macroglobulinaemia"],"prefix":"10.1111","volume":"154","author":[{"given":"Steven P.","family":"Treon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Hanzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leukothea","family":"Ioakimidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigitas J.","family":"Verselis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary R.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiuyi","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Manning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Sheehy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Turnbull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,5,12]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10764"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.754"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-172080"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190410001723287"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2005.n.014"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12846"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.7865"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07892.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00352843"},{"key":"e_1_2_7_11_1","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.4049\/jimmunol.156.8.2948","article-title":"A triallelic Fc gamma receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc gamma RIIIa","volume":"156","author":"de Haas M.","year":"1996","journal-title":"Journal of Immunology"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2007.n.004"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.n.016"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2006.n.013"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.3.1109"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.4905"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.9721"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.6315"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.4118"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0469"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-300863"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-174961"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.2015"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225979"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2008.02.001"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116022"},{"key":"e_1_2_7_27_1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood.V114.22.111.111","article-title":"Fc gamma receptor 3A genotype predicts overall survival for follicular lymphoma patients treated on Southwest Oncology Group Trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone","volume":"114","author":"Persky D.O.","year":"2009","journal-title":"Blood"},{"key":"e_1_2_7_28_1","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.8065","article-title":"Predictive value of FCGR3A genotype on response to rituximab induction and maintenance therapy in follicular non\u2010Hodgkin\u2019s lymphoma","volume":"28","author":"Pierz K.","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.19.1.275"},{"key":"e_1_2_7_30_1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1182\/blood.V112.11.234.234","article-title":"A phase I\/II study of RO5072759 (GA101) in patients with relapsed\/refractory CD20+ malignant disease","volume":"112","author":"Salles G.","year":"2008","journal-title":"Blood"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-174359"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.059"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi022"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-150854"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0862"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-177329"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.4677"},{"key":"e_1_2_7_38_1","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1182\/blood.V114.22.3750.3750","article-title":"Maintenance rituximab is associated with improved progression free and overall survival in Waldenstrom\u2019s macroglobulinaemia","volume":"114","author":"Treon S.P.","year":"2009","journal-title":"Blood"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.176"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.172.1.19"},{"key":"e_1_2_7_41_1","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.4049\/jimmunol.147.4.1338","article-title":"A single amino acid in the second Ig\u2010like domain of the human Fc gamma receptor II is critical for human IgG2 binding","volume":"147","author":"Warmerdam P.A.","year":"1991","journal-title":"Journal of Immunology"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.013"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190902829441"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00216392"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119616"},{"key":"e_1_2_7_46_1","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.8112","article-title":"Activity of the CD20\u2010directed monoclonal antibody GA101 relative to rituximab in Waldenstrom\u2019s macroglobulinaemia (WM), and applicability to patients expressing Fc\u03b3RIIIA\u2010158\u2003F\/F","volume":"28","author":"Yang G.","year":"2010","journal-title":"Journal of Clinical Oncology"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2011.08726.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2011.08726.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T22:10:23Z","timestamp":1697407823000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2011.08726.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,12]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["10.1111\/j.1365-2141.2011.08726.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08726.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,12]]},"assertion":[{"value":"2011-05-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}